New research suggests that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle programs.
Findings released in a major medical journal points out that while obese people can lose substantial amounts of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People using these medications should be informed of the danger of quick rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting weight in about a year and a half.
Analyzing Treatments
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with other pills.
Scientists emphasize that people who lose weight through dieting usually see a less rapid creep back—approximately 100 grams monthly—after stopping.
Explaining the Fast Rebound
Experts suggest the mechanism of the jabs is key to understanding the amplified regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means appetite is unsuppressed, making excessive eating far more likely."
A Lifelong Condition?
The NHS advise the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, considering the high risk of relapse, the treatment is often long-term.
This view is echoed by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Users who have discontinued the medication explain a powerful return of cravings.
"I experienced a trigger flipping and you become ravenous," described one woman.
This challenge is worsened if patients have not adopted lasting lifestyle or habit modifications during treatment.
Significant Use
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among women than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians stress that while the jabs are effective tools for shedding pounds, they are not a magic cure and long-term success relies on integrated lifestyle support.
